TY -的T1 -从2013年到2017年实现当前肌张力障碍的分类(p4.8 - 013) JF -神经学乔-神经学六世- 92 - 15补充SP - p4.8 - 013 AU -阿尔贝托·艾博年盟San首页skriti Sasikumar AU - Joachim克劳斯AU -阿方索法萨诺Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_supplement/p4.8 013. -抽象N2 -目的:评估自2013年公布的研究肌张力障碍分类是否已经适应了新的术语,并区分容易出错的类型的研究。背景:在肌张力障碍的分类方式有差异的文献作为文章继续参考旧的标准,或未能正确使用2013年的标准。设计/方法:我们进行了系统综述肌张力障碍的文献和区分研究使用新的分类正确,错误在实施新的分类,或继续使用旧的分类方法。结果:990篇文章包括在这项研究中,59.8%使用正确的分类,31.3%混合使用术语,8.9%继续使用旧的分类。Articles relating to surgery were significantly less likely to use the new classification correctly (p<0.003). The yearly rate of articles properly using the new classification revealed an upward trend.Conclusions: The 2013 classification has been adapted well in the literature and continues to show an upward trend in its use.Disclosure: Dr. Albanese has nothing to disclose. Dr. Sasikumar has nothing to disclose. Dr. Krauss has nothing to disclose. Dr. Fasano has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie, Boston Scientific, Medtronic, Sunovion, Ipsen, UCH pharma, Chiesi. Dr. Fasano has received compensation for serving on the Board of Directors of Abbvie, Boston Scientific, Medtronic, Sunovion, Ipsen, UCH pharma, Chiesi. Dr. Fasano has received royalty, license fees, or contractual rights payments from Springer. Dr. Fasano has received research support from Abbvie, Boston Scientific, Medtronic. ER -